MEMBER'S LOGINX
| Invalid Username / Password | ||||||||
| Invalid Captcha | ||||||||
|
||||||||
| Sign Up | Forgot Password? | ||||||||
- Home
- Research It
- Compare Company
- Indian - pharmaceuticals
- GLAND PHARMA - ZYDUS LIFESCIENCES
GLAND PHARMA vs ZYDUS LIFESCIENCES - Comparison Results
Current Valuations
| GLAND PHARMA | ZYDUS LIFESCIENCES | GLAND PHARMA/ ZYDUS LIFESCIENCES |
|||
|---|---|---|---|---|---|
| P/E (TTM) | x | 42.4 | 22.2 | 191.2% | View Chart |
| P/BV | x | 3.4 | 4.8 | 69.9% | View Chart |
| Dividend Yield | % | 1.1 | 0.3 | 355.0% |
Financials
 GLAND PHARMA  ZYDUS LIFESCIENCES |
| EQUITY SHARE DATA | |||||
|---|---|---|---|---|---|
| GLAND PHARMA Mar-24 |
ZYDUS LIFESCIENCES Mar-24 |
GLAND PHARMA/ ZYDUS LIFESCIENCES |
5-Yr Chart Click to enlarge
|
||
| High | Rs | 2,196 | 1,030 | 213.1% | |
| Low | Rs | 862 | 483 | 178.5% | |
| Sales per share (Unadj.) | Rs | 343.9 | 194.3 | 177.0% | |
| Earnings per share (Unadj.) | Rs | 46.9 | 38.1 | 123.2% | |
| Cash flow per share (Unadj.) | Rs | 67.8 | 45.7 | 148.5% | |
| Dividends per share (Unadj.) | Rs | 20.00 | 3.00 | 666.7% | |
| Avg Dividend yield | % | 1.3 | 0.4 | 329.9% | |
| Book value per share (Unadj.) | Rs | 529.6 | 197.1 | 268.7% | |
| Shares outstanding (eoy) | m | 164.71 | 1,006.23 | 16.4% | |
| Bonus / Rights / Conversions | 0 | 0 | - | ||
| Price / Sales ratio | x | 4.4 | 3.9 | 114.2% | |
| Avg P/E ratio | x | 32.6 | 19.9 | 164.1% | |
| P/CF ratio (eoy) | x | 22.5 | 16.6 | 136.1% | |
| Price / Book Value ratio | x | 2.9 | 3.8 | 75.2% | |
| Dividend payout | % | 42.6 | 7.9 | 541.3% | |
| Avg Mkt Cap | Rs m | 251,781 | 761,065 | 33.1% | |
| No. of employees | `000 | NA | NA | - | |
| Total wages/salary | Rs m | 12,569 | 27,890 | 45.1% | |
| Avg. sales/employee | Rs Th | 0 | 0 | - | |
| Avg. wages/employee | Rs Th | 0 | 0 | - | |
| Avg. net profit/employee | Rs Th | 0 | 0 | - | |
| INCOME DATA | |||||
|---|---|---|---|---|---|
| Net Sales | Rs m | 56,647 | 195,474 | 29.0% | |
| Other income | Rs m | 1,702 | 3,694 | 46.1% | |
| Total revenues | Rs m | 58,350 | 199,168 | 29.3% | |
| Gross profit | Rs m | 13,331 | 52,848 | 25.2% | |
| Depreciation | Rs m | 3,446 | 7,641 | 45.1% | |
| Interest | Rs m | 262 | 812 | 32.3% | |
| Profit before tax | Rs m | 11,325 | 48,089 | 23.6% | |
| Minority Interest | Rs m | 0 | 0 | - | |
| Prior Period Items | Rs m | 0 | 0 | - | |
| Extraordinary Inc (Exp) | Rs m | 0 | 0 | - | |
| Tax | Rs m | 3,601 | 9,775 | 36.8% | |
| Profit after tax | Rs m | 7,725 | 38,314 | 20.2% | |
| Gross profit margin | % | 23.5 | 27.0 | 87.0% | |
| Effective tax rate | % | 31.8 | 20.3 | 156.4% | |
| Net profit margin | % | 13.6 | 19.6 | 69.6% | |
| BALANCE SHEET DATA | |||||
|---|---|---|---|---|---|
| Current assets | Rs m | 56,452 | 114,198 | 49.4% | |
| Current liabilities | Rs m | 13,984 | 53,397 | 26.2% | |
| Net working cap to sales | % | 75.0 | 31.1 | 241.0% | |
| Current ratio | x | 4.0 | 2.1 | 188.8% | |
| Inventory Days | Days | 50 | 30 | 168.9% | |
| Debtors Days | Days | 100 | 97 | 103.0% | |
| Net fixed assets | Rs m | 49,657 | 161,352 | 30.8% | |
| Share capital | Rs m | 165 | 1,006 | 16.4% | |
| "Free" reserves | Rs m | 87,060 | 197,289 | 44.1% | |
| Net worth | Rs m | 87,225 | 198,295 | 44.0% | |
| Long term debt | Rs m | 1,065 | 0 | - | |
| Total assets | Rs m | 106,108 | 276,366 | 38.4% | |
| Interest coverage | x | 44.2 | 60.2 | 73.4% | |
| Debt to equity ratio | x | 0 | 0 | - | |
| Sales to assets ratio | x | 0.5 | 0.7 | 75.5% | |
| Return on assets | % | 7.5 | 14.2 | 53.2% | |
| Return on equity | % | 8.9 | 19.3 | 45.8% | |
| Return on capital | % | 13.1 | 24.7 | 53.2% | |
| Exports to sales | % | 63.1 | 43.0 | 146.7% | |
| Imports to sales | % | 0 | 9.9 | 0.0% | |
| Exports (fob) | Rs m | 35,764 | 84,117 | 42.5% | |
| Imports (cif) | Rs m | NA | 19,274 | 0.0% | |
| Fx inflow | Rs m | 35,764 | 84,117 | 42.5% | |
| Fx outflow | Rs m | 9,401 | 19,274 | 48.8% | |
| Net fx | Rs m | 26,363 | 64,843 | 40.7% | |
| CASH FLOW | |||||
|---|---|---|---|---|---|
| From Operations | Rs m | 9,968 | 32,279 | 30.9% | |
| From Investments | Rs m | -17,569 | -14,752 | 119.1% | |
| From Financial Activity | Rs m | -7,994 | -18,104 | 44.2% | |
| Net Cashflow | Rs m | -15,518 | -748 | 2,074.6% | |
Share Holding
| Indian Promoters | % | 0.0 | 75.0 | - | |
| Foreign collaborators | % | 51.8 | 0.0 | - | |
| Indian inst/Mut Fund | % | 39.8 | 18.2 | 219.3% | |
| FIIs | % | 4.5 | 7.5 | 59.6% | |
| ADR/GDR | % | 0.0 | 0.0 | - | |
| Free float | % | 48.2 | 25.0 | 192.5% | |
| Shareholders | 122,358 | 370,863 | 33.0% | ||
| Pledged promoter(s) holding | % | 0.0 | 0.0 | - |
Compare GLAND PHARMA With: DIVIS LABORATORIES SUN PHARMA CIPLA DR. REDDYS LAB MANKIND PHARMA
More on GLAND PHARMA vs Cadila Healthcare
No comparison is complete without understanding how the stock prices have performed over a period of time.
Here's a brief comparison:
GLAND PHARMA vs Cadila Healthcare Share Price Performance
| Period | GLAND PHARMA | Cadila Healthcare | S&P BSE HEALTHCARE |
|---|---|---|---|
| 1-Day | 0.34% | 0.21% | 0.67% |
| 1-Month | 6.07% | -5.80% | -3.33% |
| 1-Year | 9.17% | 48.91% | 43.33% |
| 3-Year CAGR | -20.46% | 27.56% | 19.82% |
| 5-Year CAGR | -0.47% | 31.19% | 26.27% |
* Compound Annual Growth Rate
Here are more details on the GLAND PHARMA share price and the Cadila Healthcare share price.
Moving on to shareholding structures...
The promoters of GLAND PHARMA hold a 51.8% stake in the company. In case of Cadila Healthcare the stake stands at 75.0%.
To review how promoter stakes have changed over time, and how much of the promoter stake is pledged, please see the shareholding pattern of GLAND PHARMA and the shareholding pattern of Cadila Healthcare.
Finally, a word on dividends...
In the most recent financial year, GLAND PHARMA paid a dividend of Rs 20.0 per share. This amounted to a Dividend Payout ratio of 42.6%.
Cadila Healthcare paid Rs 3.0, and its dividend payout ratio stood at 7.9%.
You may visit here to review the dividend history of GLAND PHARMA, and the dividend history of Cadila Healthcare.
For a sector overview, read our pharmaceuticals sector report.
Today's Market
![Sensex Today Ends 239 Points Higher | Nifty Above 23,500 | HDFC Bank & Tech Mahindra Top Gainers]()
Sensex Today Ends 239 Points Higher | Nifty Above 23,500 | HDFC Bank & Tech Mahindra Top Gainers(Closing)
On Tuesday, Indian share markets traded on a positive note throughout the session and ended marginally higher.
ABOUT EQUITYMASTER
Since 1996, Equitymaster has been the source for honest and credible opinions on investing in India. With solid research and in-depth analysis Equitymaster is dedicated towards making its readers- smarter, more confident and richer every day. Here's why hundreds of thousands of readers spread across more than 70 countries Trust Equitymaster.
PREMIUM PRODUCTS
QUICK LINKS
POPULAR TOPICS
- Multibagger Penny Stocks
- Basics of Value Investing
- Benjamin Graham
- How to Invest in Gold
- How to Invest in Silver
- Best Stocks to Buy Today
- Best Small-cap Stocks to Buy
- Best Bluechip Stocks to Buy
- Guide to Penny Stocks
- How to Invest in the Share Market
- Warren Buffett - The Value Investor
- Pick the Best Multibagger Stocks
TRENDING TOPICS
Copyright © Equitymaster Research Private Limited (formerly Equitymaster Agora Research Private Limited).
Whitelist | Refer | Terms | Privacy | Contact | About | Sitemap
Equitymaster Research Private Limited (formerly Equitymaster Agora Research Private Limited) (Research Analyst)
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.
103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Email: info@equitymaster.com. Website: www.equitymaster.com.
CIN:U74999MH2007PTC175407
Name of the Compliance & Grievance Officer: Ms Sonal Ramachandran
Telephone: +91-22-61434003 | Email: compliance@equitymaster.com
LEGAL DISCLAIMER:
Investment in securities market are subject to market risks. Read all the related documents carefully before investing.
Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.
All rights reserved. Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.
Equitymaster Research Private Limited (formerly Equitymaster Agora Research Private Limited) (Research Analyst) bearing Registration No. INH000000537 (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA, Canada or the European Union countries, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.